Cited by 794Pharmacology and Obesity TreatmentObesity, Physical Activity, DietObesity and Health Practices

Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity

Open access
Wadden, Thomas A., Berkowitz, Robert I., Womble, Leslie G., Sarwer, David B., Phelan, Suzanne, Cato, Robert K., Hesson, Louise A., Osei, Suzette Y. +2 more·2005·New England Journal of Medicine

Abstract

BACKGROUND: Weight-loss medications are recommended as an adjunct to a comprehensive program of diet, exercise, and behavior therapy but are typically prescribed with minimal or no lifestyle modification. This practice is likely to limit therapeutic benefits. METHODS: In this one-year trial, we randomly assigned 224 obese adults to receive 15 mg of sibutramine per day alone, delivered by a primary care provider in eight visits of 10 to 15 minutes each; lifestyle-modification counseling alone, delivered in 30 group sessions; sibutramine plus 30 group sessions of lifestyle-modification counseling (i.e., combined therapy); or sibutramine plus brief lifestyle-modification counseling delivered by a primary care provider in eight visits of 10 to 15 minutes each. All subjects were prescribed a diet of 1200 to 1500 kcal per day and the same exercise regimen. RESULTS: At one year, subjects who received combined therapy lost a mean (+/-SD) of 12.1+/-9.8 kg, whereas those receiving sibutramine alone lost 5.0+/-7.4 kg, those treated by lifestyle modification alone lost 6.7+/-7.9 kg, and those receiving sibutramine plus brief therapy lost 7.5+/-8.0 kg (P<0.001). Those in the combined-therapy group who frequently recorded their food intake lost more weight than those who did so infrequently (18.1+/-9.8 kg vs. 7.7+/-7.5 kg, P=0.04). CONCLUSIONS: The combination of medication and group lifestyle modification resulted in more weight loss than either medication or lifestyle modification alone. The results underscore the importance of prescribing weight-loss medications in combination with, rather than in lieu of, lifestyle modification.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa050156

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002;346:591-602.
  2. Brownell KD, Wadden TA. The LEARN program for weight control: special medica- tion edition. Dallas: American Health Pub- lishing, 1999.
  3. Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R, Steinberg C. Benefits of lifestyle modification in the pharmacologic treatment of obesity. Arch Intern Med 2001; 161:218-27.

Cited by

Sorted by citations

Authors
Wadden, T. A., Berkowitz, R. I., Womble, L. G., Sarwer, D. B., Phelan, S., Cato, R. K., Hesson, L. A., Osei, S. Y., Kaplan, R., & Stunkard, A. J.
Affiliations
  • University of Pennsylvania (US)
  • Children's Hospital of Philadelphia (US)
  • Brown University (US)
  • GlaxoSmithKline (United States) (US)
Venue
New England Journal of Medicine
Published
2005-11-17
Volume
353
Issue
20
Pages
2111-2120
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2133783450
Cited by
794
References
27
Citations by year
2026: 12 · 2025: 14 · 2024: 18 · 2023: 17 · 2022: 23 · 2021: 18 · 2020: 18 · 2019: 25 · 2018: 18 · 2017: 28 · 2016: 37 · 2015: 33 · 2014: 38 · 2013: 51 · 2012: 53
FWCI
46.38
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5k24dk065018-10)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK056124, DK-56124, DK065018)
Topics
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
  • Health Sciences › Health Professions › Pharmacy › Obesity and Health Practices
Keywords
obesity, anti-obesity drugs, sibutramine, lifestyle modification, group counseling, combination therapy, weight loss, primary care, diet and exercise
MeSH terms
Adult, Appetite Depressants, Cardiovascular Diseases, Combined Modality Therapy, Counseling, Cyclobutanes, Female, Humans, Life Style, Male, Middle Aged, Obesity, Psychotherapy, Group, Risk Factors, Weight Loss, Exercise, Selective Serotonin Reuptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review